Gimv and several other venture capital investors have sold Belgian biotech ActoGenix to US-based Intrexon Corporate for a total consideration of $60m.
Asset is reportedly due to come to market in 2021, with the sale process most likely starting in H1
Redalpine has led a series-A funding round for Germany-headquartered pet healthcare startup Felmo.
GP intends to boost the company's growth and consolidate its market position in the Benelux and DACH regions
GP is deploying equity via WMS III and is investing with future managing director Holger Schmitz